glp-1 ibd 🚨 RA use in is rising fast In this 14-month repeated survey of patients with IBD: 📈 GLP-1 RA use rose 5-fold ⚖️ Median BMI fell from 35.3 → 31.2 Adjunctive GLP1 Receptor Agonists in

Major semaglutide weight loss trials (STEP 14) did not measure cortisol as a primary or secondary outcome

Both involve bioactive peptides, but they work differently, target different goals, and follow very different evidence and regulatory pathways

Overall Safety and Tolerability Assessment The primary safety conclusion from the comprehensive trial program was unambiguous: AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo

Share this with a colleague who could use a deprescribing refresher

But it is not a casual intervention

Additionally, a randomized controlled trial revealed that a combination of flavan-3-ols and isoflavones enhanced insulin sensitivity and lipoprotein profiles compared to placebo, further lowering the estimated 10-year CVD risk in women with type 2 diabetes (Peter et al., 2012)